Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 19 of 19 publications.

Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey. J Dermatolog Trea. 2024 Jun 24;35(1):2366532. doi: 10.1080/09546634.2024.2366532

Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.

Kwatra SG, Lio P, Weidinger S, Calimlim B, Ladizinski B, Vigna N, Botha W, Mansfield C. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Trea. 2023 Dec 1;34(1):2222201. doi: 10.1080/09546634.2023.2222201

Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382

Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Trea. 2021 Oct 6;1-9. doi: 10.1080/09546634.2021.1940810

Chen YW, Ni L, Ospina-Forero L. Visualising internal migration flows across local authorities in England and Wales. EPA. 2021 Jun;53(4):616-8. doi: 10.1177/0308518X20968568

Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007

Chen YW, Ni L, Xu DL, Yang JB. Visualising regional disparities in the risk of COVID-19 at different phases of lockdown in England. EPA. 2021 Jan 19;53(5):883-6. doi: 10.1177%2F0308518X20984165

Martin SA, Brown TM, Fehnel S, Deal LS, Katz EG, Chiou CF. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis. J Dermatolog Trea. 2020 Aug;31(5):484-30708. doi: 10.1080/09546634.2020.1713971

Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700

Giner-Soriano M, Teixido C, Marsal JR, Diez O, Pera H, Vlacho B, Morros R, working group for the clinical trial IJG-KOH-2014. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children. J Dermatolog Trea. 2019 Dec;30(8):750-6. doi: 10.1080/09546634.2019.1573305

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464

Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.

Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492

Bowater RJ, Hartley LC, Lilford RJ. Are cardiovascular trial results systematically different between North America and Europe? A study based on intra-meta-analysis comparisons. Arch Cardiovasc Dis. 2015 Jan;108(1):23-38. doi: 10.1016/j.acvd.2014.03.005

Davis AE, Mehrota S, Ladner DP, Kilambi V, Friedewald JJ. Changes in geographic disparity in kidney transplantation since the final rule. Transplantation. 2014 Nov 15;98(9):931-6. doi: 10.1097/TP.0000000000000446

Davis AE, Mehrotra S, McElroy LM, Friedewald JJ, Skaro AI, Lapin B, Kang R, Holl JL, Abecassis MM, Ladner DP. The extent and predictors of waiting time geographic disparity in kidney transplantation in the United States. Transplantation. 2014 May 27;97(10):1049-57. doi: 10.1097/01.tp.0000438623.89310.dc

Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, Mallat MJ, Borm G, Weimar W, Hoitsma AJ, de Fijter JW. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011 Apr 27;91(8):869-74.

Nguyen USDT, Rothman KJ, Demissie S, Jackson DJ, Lang JM, Ecker JL. Transfers among women intending a birth center delivery in the San Diego birth center study. J Midwifery Womens Health. 2009 Mar 1;54(2):104-10.